×

Biotech and Pharmaceuticals Life Sciences

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known...

  • March 27- The U.S. Food and Drug Administration on Monday approved Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer. The U.S. biopharmaceutical company's shares were up 7.78 percent at $168.9 in extended trading. Tesaro expects to launch niraparib in the United States in late April.

  • AUSTIN, Texas _ Aeglea Biotherapeutics Inc. on Thursday reported a loss of $5.5 million in its fourth quarter. The Austin, Texas- based company said it had a loss of 41 cents per share. Keywords: Aeglea Biotherapeutics, Earnings Report.

  • The Food and Drug Administration said it approved Bavencio, known chemically as avelumab, to treat metastatic Merkel cell carcinoma in patients 12 years and older. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in a statement. About 1,600 people in the United States are diagnosed with MCC every year, according to the National Cancer...

  • PALO ALTO, Calif. _ Eiger BioPharmaceuticals Inc. on Thursday reported a loss of $12.8 million in its fourth quarter. The Palo Alto, California- based company said it had a loss of $1.53 per share. Keywords: Eiger BioPharmaceuticals, Earnings Report.

  • TEL AVIV, Israel _ Galmed Pharmaceuticals Ltd. on Thursday reported a loss of $4.8 million in its fourth quarter. Three analysts surveyed by Zacks expected $216,000. Access a Zacks stock report on GLMD at https://www.zacks.com/ap/GLMD.

  • Stephen Hawking in London in 2015.

    British physicist Stephen Hawking fears he won't be welcome in the U.S. due to his criticism of how President Trump is treating scientists.

  • AURORA, Ontario _ Helix Biopharma Corp. on Friday reported a loss of $2 million in its fiscal second quarter. The Aurora, Ontario- based company said it had a loss of 2 cents per share. Keywords: Helix Biopharma, Earnings Report.

  • Hello, what a better night's sleep?

    James Proud, Hello founder & CEO talks about a tech device that monitors and improves sleep.

  • *British company licenses two COPD drugs from AstraZeneca. LONDON, March 17- Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease, a progressive lung condition affecting millions of people, for up to $230 million. Circassia's Chief Executive Steve Harris said Tudorza, a bronchodilator...

  • VALENCIA, Calif. _ MannKind Corp. on Thursday reported fourth-quarter net income of $54 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Valencia, California- based company said it had net income of 56 cents. For the year, the company reported net income of $125.7 million, or $1.36 per share, swinging to a profit in the period.

  • SOUTH PLAINFIELD, N.J. _ PTC Therapeutics Inc. on Thursday reported a loss of $26.8 million in its fourth quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 99 cents per share. PTC Therapeutics shares have decreased slightly since the beginning of the year.

  • "The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive," said researcher Matthew Snape of the University of Oxford. That is different from another Ebola vaccine from Merck, which was the first to prove effective in preventing human infection during a large trial in Guinea last year. Scientists have been racing to...

  • March 9- INTERVIEW-NOVO NORDISK'S CEO SAYS LOOKING FOR DEALS TO BROADEN GROWTH OPPORTUNITIES NOVO NORDISK'S CEO SAYS ANY ACQUISITIONS LIKELY TO BE "LOW SINGLE-DIGIT BILLIONS OF DOLLARS". Novo Nordisk's new chief executive is looking at making acquisitions to broaden the Danish drugmaker's product line-up, in a change of tack that reflects a need for fresh...

  • March 7- Shares of U.S. pharmaceutical and biotechnology companies fell on Tuesday after President Donald Trump said he was working on a "new system" to reduce prices in the industry, without providing details of his plan. "Im skeptical about what it is that he might do that would actually have a material impact on drug prices," said Paul Heldman, managing partner at...

  • PARIS, March 6- Sanofi has struggled with a reputation as a laggard in finding new drugs but its global research chief believes the imminent approval of a game-changing eczema medicine signals a new era for the French company. Dupilumab has impressed doctors in a series of clinical trials over the past year and is widely expected to win a U.S. green light by the...

  • ZURICH, March 1- Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview. Peter Hammerman joined the Swiss firm in late 2016, becoming the fourth leading cancer scientist to be poached in...

  • *270 mln euros to be invested. PARIS, Feb 27- French drugmaker Sanofi and Swiss manufacturer Lonza will invest 270 million euros in a new large-scale biologics facility that will produce monoclonal antibodies by 2020, the two companies said on Monday. Pending regulatory approvals, the facility- which will be established through a 50-50 joint venture- will be...

  • Feb 21- Drugmaker Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in an agreement with JANA Partners LLC, an activist investor holding less than 1 percent of the company's stock. The stock fell 1.8 percent to $53.59 on Tuesday. New York- based JANA owned 3.9 million shares of Bristol-Myers as of Dec. 31, a $226 million stake well...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...